Serine/threonine-protein kinase PAK 4 is an enzyme that in humans is encoded by the PAK4 gene.[5][6][7]
Quick Facts Available structures, PDB ...
PAK4 |
---|
|
Available structures |
---|
PDB | Ortholog search: PDBe RCSB |
---|
List of PDB id codes |
---|
2BVA, 2CDZ, 2J0I, 2OV2, 2Q0N, 2X4Z, 4APP, 4FIE, 4FIF, 4FIG, 4FIH, 4FII, 4FIJ, 4JDH, 4JDI, 4JDJ, 4JDK, 4L67, 4NJD, 4O0V, 4O0X, 4O0Y, 5BMS, 4XBU, 4XBR |
|
|
Identifiers |
---|
Aliases | PAK4, p21 (RAC1) activated kinase 4 |
---|
External IDs | OMIM: 605451; MGI: 1917834; HomoloGene: 4300; GeneCards: PAK4; OMA:PAK4 - orthologs |
---|
|
|
|
|
|
Wikidata |
|
Close
PAK4 is one of six members of the PAK family of serine/threonine kinases which are divided into group I (PAK1, PAK2 and PAK3) and group II (PAK4, PAK6 and PAK5/7).[8][9] PAK4 localizes in sub-cellular domains of the cytoplasm and nucleus.[8][10][11] PAK4 regulates cytoskeleton remodeling, phenotypic signaling and gene expression, and affects directional motility, invasion, metastasis, and growth.[12] Similar to PAK1, PAK4-signaling-dependent cellular functions also regulate both physiologic and disease processes such as cancer, as PAK4 is overexpressed and/or hyperstimulated in human cancer, at-large.[13][14]
PAK4, the founding member of Group II PAK member, was cloned and identified by Minden A. and colleagues in 1998 using a PCR-based strategy from a cDNA library prepared from Jurkett cells.[8]
The group II PAKs have less coding exons compared with group I PAKs, highlights the potential structural and functional differences between two group of PAKs. The human PAK4 is about 57-kb in length with 13 exons. The PAK4 generates 12 transcripts of which 10 coding transcripts are predicted to code proteins of about 438 to 591 amino acids long, while remaining two transcripts are non-coding in nature. In contrast to human PAK4, murine PAK4 contains four transcripts - two coding for 593 amino acids long polypeptides and two are non-coding RNA transcripts.
The core domains of PAK4 include, a kinase domain in the C-terminal region, a p21-binding domain (PBD), and a newly defined auto-inhibitory domain (AID) [15] or an AID-like pseudosubstrate sequence (PS) domain.[16]
PAK4 activity is stimulated by upstream activators and signals, including by HGF,[17] PKD,[18][19] PKA,[20] CDK5RAP3,[21] and SH3RF2.[22]
In addition to other mechanisms, PAK4 functions are mediated though phosphorylation of its effector proteins, including, LIMK1-Thr508,[23] integrin β5-Ser759/Ser762,[24] p120-catenin-Ser288,[25] superior cervical ganglia 10 (SCG10)-Ser50,[26] GEF-H1-Ser810[11][27] β-catenin-Ser675,[10] and Smad2-Ser465.[28]
PAK4 and/or PAK4-dependent signals also modulate the expression of genomic targets, including p57Kip2.[29]
The PAK4 activity and expression has been shown to be inhibited by chemical inhibitors such as PF-3758309,[30] LCH-7749944,[31] glaucarubinone,[32] KY-04031,[33] KY-04045,[34] 1-phenanthryl-tetrahydroisoquinoline derivatives,[35] (-)-β-hydrastine,[36] Inka1,[37] GL-1196,[38] GNE-2861,[39] and microRNAs such as miR-145,[40] miR-433,[41] and miR-126.[42]
PAK proteins, a family of serine/threonine p21-activating kinases, include PAK1, PAK2, PAK3 and PAK4. PAK proteins are critical effectors that link Rho GTPases to cytoskeleton reorganization and nuclear signaling. They serve as targets for the small GTP binding proteins Cdc42 and Rac and have been implicated in a wide range of biological activities. PAK4 interacts specifically with the GTP-bound form of Cdc42Hs and weakly activates the JNK family of MAP kinases. PAK4 is a mediator of filopodia formation and may play a role in the reorganization of the actin cytoskeleton. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.[7] PAK4 has been shown to be repressed at translational level by miR-24.[43]
PAK4 regulates cellular processes by its scaffolding activity and/or by phosphorylation of effector substrates, which in-turn, set-up a cascades of biochemical events cumulating into a cellular phenotypic response. Examples of PAK4-regulated cellular processes include, dynamic reorganization of actin,[23] and microtubule fibers,[26] anchorage-independent growth,[44] filopodium formation,[8] and cell motility.
- ITGB5,[45] cell survival[46] embryonic development,[47] supports stem cell-like phenotypes,[48] and gene expression.[10] Modulation of PAK4 signaling has been shown to lead to significant functional implications in a number of disease conditions, exemplified by oncogenesis,[28] cancer cell invasion and metastasis.[26][49]
PAK4 has been shown to interact with:
Ha BH, Davis MJ, Chen C, Lou HJ, Gao J, Zhang R, Krauthammer M, Halaban R, Schlessinger J, Turk BE, Boggon TJ (October 2012). "Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate". Proceedings of the National Academy of Sciences of the United States of America. 109 (40): 16107–12. Bibcode:2012PNAS..10916107H. doi:10.1073/pnas.1214447109. PMC 3479536. PMID 22988085.
Park MH, Lee HS, Lee CS, You ST, Kim DJ, Park BH, Kang MJ, Heo WD, Shin EY, Schwartz MA, Kim EG (May 2013). "p21-Activated kinase 4 promotes prostate cancer progression through CREB". Oncogene. 32 (19): 2475–82. doi:10.1038/onc.2012.255. PMID 22710715. S2CID 24463782.
Kim TW, Kang YK, Park ZY, Kim YH, Hong SW, Oh SJ, Sohn HA, Yang SJ, Jang YJ, Lee DC, Kim SY, Yoo HS, Kim E, Yeom YI, Park KC (March 2014). "SH3RF2 functions as an oncogene by mediating PAK4 protein stability". Carcinogenesis. 35 (3): 624–34. doi:10.1093/carcin/bgt338. PMID 24130170.
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM (July 2008). "A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF". Cellular Signalling. 20 (7): 1320–8. doi:10.1016/j.cellsig.2008.02.021. PMID 18424072.
Wong LE, Reynolds AB, Dissanayaka NT, Minden A (August 2010). "p120-catenin is a binding partner and substrate for Group B Pak kinases". Journal of Cellular Biochemistry. 110 (5): 1244–54. doi:10.1002/jcb.22639. PMID 20564219. S2CID 24567609.
Wang C, Li Y, Zhang H, Liu F, Cheng Z, Wang D, Wang G, Xu H, Zhao Y, Cao L, Li F (June 2014). "Oncogenic PAK4 regulates Smad2/3 axis involving gastric tumorigenesis". Oncogene. 33 (26): 3473–84. doi:10.1038/onc.2013.300. PMID 23934187. S2CID 6284169.
Li Y, Wang D, Zhang H, Wang C, Dai W, Cheng Z, Wang G, Li F (October 2013). "P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer". Anatomical Record. 296 (10): 1561–7. doi:10.1002/ar.22754. PMID 23873832. S2CID 33508556.
Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I, Christensen JG, Martinez R, Kephart SE, Marakovits J, Karlicek S, Bergqvist S, Smeal T (May 2010). "Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth". Proceedings of the National Academy of Sciences of the United States of America. 107 (20): 9446–51. Bibcode:2010PNAS..107.9446M. doi:10.1073/pnas.0911863107. PMC 2889050. PMID 20439741.
Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng M, Zhao D, Li F (April 2012). "LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells". Cancer Letters. 317 (1): 24–32. doi:10.1016/j.canlet.2011.11.007. PMID 22085492.
Ryu BJ, Kim S, Min B, Kim KY, Lee JS, Park WJ, Lee H, Kim SH, Park S (July 2014). "Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor". Cancer Letters. 349 (1): 45–50. doi:10.1016/j.canlet.2014.03.024. PMID 24704155.
Park JK, Kim S, Han YJ, Kim SH, Kang NS, Lee H, Park S (June 2016). "The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor". Bioorganic & Medicinal Chemistry Letters. 26 (11): 2580–3. doi:10.1016/j.bmcl.2016.04.037. PMID 27117431.
Song S, Li X, Guo J, Hao C, Feng Y, Guo B, Liu T, Zhang Q, Zhang Z, Li R, Wang J, Lin B, Li F, Zhao D, Cheng M (March 2015). "Design, synthesis and biological evaluation of 1-phenanthryl-tetrahydroisoquinoline derivatives as novel p21-activated kinase 4 (PAK4) inhibitors". Organic & Biomolecular Chemistry. 13 (12): 3803–18. doi:10.1039/c5ob00037h. PMID 25705811. S2CID 205989042.
Wang Z, Zhang X, Yang Z, Du H, Wu Z, Gong J, Yan J, Zheng Q (October 2012). "MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells". Biochemical and Biophysical Research Communications. 427 (3): 444–9. doi:10.1016/j.bbrc.2012.06.123. PMID 22766504.
Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY (January 2015). "MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)". Molecular and Cellular Biochemistry. 399 (1–2): 77–86. doi:10.1007/s11010-014-2234-9. PMID 25410752. S2CID 17307710.
Amelio I, Lena AM, Viticchiè G, Shalom-Feuerstein R, Terrinoni A, Dinsdale D, Russo G, Fortunato C, Bonanno E, Spagnoli LG, Aberdam D, Knight RA, Candi E, Melino G (October 2012). "miR-24 triggers epidermal differentiation by controlling actin adhesion and cell migration". The Journal of Cell Biology. 199 (2): 347–63. doi:10.1083/jcb.201203134. PMC 3471232. PMID 23071155.
Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3 (1): 89. doi:10.1038/msb4100134. PMC 1847948. PMID 17353931.